Similar Articles
Trial of Fingolimod Versus Interferon Beta-1a in Pediatric Multiple Sclerosis
Miraç Ayşen Ünsal
DOI: 10.4274/tnd.2019.00187
The Importance of Consultation Neurology: A Patient with Anti-Glutamic Acid Decarboxylase Antibody-Associated Cerebellar Ataxia Recognized in the Psychiatry Inpatient Clinic
Zeynep Ezgi Balçık, Sezin Alpaydın Baslo, Elif Söylemez, Betül Güveli, Dilek Ataklı
DOI: 10.4274/tnd.37973
Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
Özlem Taşkapılıoğlu, Aslı Bahar Turan, Murat Albas, Ömer Faruk Turan
DOI: 10.4274/Tdn.64325
Intravenous Immunoglobulin Use in A Case of Acute Disseminated Encephalomyelitis with Concomittant Motor Axonal Neuropathy
Çağatay Öncel, Yılmaz Kıroğlu, Selahattin Gür
Side Effects of Intravenous Immunoglobulin Treatment in Neurological Disorders
Buket Oflazoğlu, Fatma Öztürk, Hatice Kayaalp Açık, Çağatay Öncel, Ülker Anadol, Hulki Forta
Tumour Necrosis Factor-Alpha Alone is not Predictive of Relapses in Multiple Sclerosis.
Egemen İDİMAN, Hakkı BAHAR, İhsan Şükrü ŞENGÜN, Göksemin ACAR, Barış BAKLAN, Murat SAYAN, Huriye AYDIN, Tuncer TOKLU, Serkan ÖZAKBAŞ
Experiences of lnterferon Beta-1b Treatment After 5-Year Follow-U
Serkan ÖZAKBAŞ, Egemen İDİMAN, Burak PAKÖZ, Berril DÖNMEZ, Utku UYSAL
Multimodal Evoked Potentialsin Follow-up of Treatment of Multiple Sclerosis With lnterferon Beta-1 a
Serkan ÖZAKBAŞ, Raif ÇAKMUR, Vesile ÖZTÜRK, Egemen İDİMAN, Fethi İDİMAN
lnterferon Beta-1b In TheTreatment Of Relapsing Remitting Multiple Sclerosis:Clinical and Magnetic Resonance lmaging Results
Serkan ÖZAKBAŞ, Egemen İDİMAN, Handan ÇAKMAKÇI, İlhami KOVANLIKAYA
lntravenous lmmunoglobulin In Guillain-Barre Syndrome
Sibel K. VELİOĞLU, Cavit BOZ, Mehmet ÖZMENOĞLU
Intravenous Immunoglobulin Treatment in Patients With Chronic Inflammatory Demyelinating Polyneuropathy
Sevim ERDEM, Kubilay VARLI, Gülay NURLU, Okay SARIBAŞ, Ersin TAN